FDA Accepts Supplemental Biologics License Application (sBLA) for KEYTRUDA ® (pembrolizumab) in Recurrent or Metastatic Head and Neck Cancer, and Grants Priority Review
< div class= " field field-type-text field-field-press-release-city field-fieldpressreleasecity " > < div class= " field-label " > Dateline City: < /div > < div class= " field-items " > < div class= " field-item odd " >
KENILWORTH, N.J. < /div > < /div > < /div > < p > KENILWORTH, N.J.--( < a target= " _blank " href= " http://www.businesswire.com " > BUSINESS WIRE < /a > )--Merck (NYSE: MRK), known as MSD outside the United States and Canada,
today announced that the U.S. Food and Drug Administration (FDA) has
accepted for review the supplemental Biologics License Application
(sBLA) for KEYTRUDA < sup > ® < /sup > (pembrolizumab), the company ’s anti-PD-1
therapy, for the treatment of patients with recurrent or metastatic head
and neck squamous cell carcinoma (HNSCC) with disease progression on or
after platinum-containing chemotherapy. < /p > < div class= " field field-type-text field-field-press-release-language field-fieldpressreleaselanguage " > < div class= " field-label " > Language: < /div > < div class= " field-items " > < div class= " field-item odd " >
English < /div > < /div > < /div > < div class= " field field-type-text field-field-press-release-contact-html field-fieldpressreleasecontacthtml " > < div class= " field-label " > Contact: < /div > < div class= " field-items " > < div class= " field-item odd " > < p > Merck < br / > Media: < br / > Pamela Eisele, 267-30...